CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors [MarketWatch]
CymaBay Therapeutics Inc. (CBAY)
Last cymabay therapeutics inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cymabay.com
Company Research
Source: MarketWatch
CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors Shares of CymaBay Therapeutics Inc. CBAY, -54.01% plummeted 43% in premarket trade Tuesday after the biotech said data from an ongoing Phase 2 trial showed patients with nonalcoholic steatohepatitis (NASH) who were treated with investigational drug seladelpar did not show significant reductions in liver fat when compared with those on a placebo. However, treatment with seladelpar did result in a reduction in biomarkers associated with liver injury, the company said. "While the reductions in liver fat were minimal, we remain encouraged by the significant improvements in biochemical markers of liver injury that we observed at week 12," said Pol Boudes, CymaBay's chief medical officer. "The 52-week liver biopsy data will allow us to understand whether the improvement in liver injury markers will translate into histological improvement. The observed improvement in markers of liver injury are consistent with
Show less
Read more
Impact Snapshot
Event Time:
CBAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CBAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CBAY alerts
High impacting CymaBay Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CBAY
News
- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer [Yahoo! Finance]Yahoo! Finance
- Global Primary Biliary Cholangitis Therapeutics Market 2024-2034 - Hospital Pharmacies Lead Distribution, But Online Pharmacies to Experience Rapid Growth Amid Digital Healthcare Boom [Yahoo! Finance]Yahoo! Finance
CBAY
Earnings
- 11/7/23 - Miss
CBAY
Sec Filings
- 3/22/24 - Form 4
- 3/22/24 - Form 4
- 3/22/24 - Form 4
- CBAY's page on the SEC website